Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma family of tumors: A Children's Oncology Group trial.

9526 Background: Topotecan and cyclophosphamide are active in relapsed Ewing sarcoma family of tumors (ESFT). The feasibility of adding these agents to standard interval compressed therapy was investigated. Methods: Patients with biopsy proven previously untreated extra-dural ESFT without distant metastases and < 31 years of age were eligible. Entry criteria were: performance status < 2, adequate organ function and written informed consent. Patients were to receive 17 cycles of intravenous chemotherapy that were to be administered at two week intervals. VCR 1.5 mg/m2 on days 1 and 8, TOPO 0.75 mg/m2 days 1-5 and CYCLO 250 mg/m2 days 1-5 (VTC), VCR identical to VTC, DOX 37.5 mg/m2on days 1-2, CYCLO 1200 mg/m2on day 1 (VDC), and IFOS 1800 mg/m2 days 1-5 and ETOP 100 mg/m2 days 1-5 (IE) were administered for 5, 5 and 7 cycles respectively in an alternating manner. Local control (LC) with surgery, radiation or both modalities occurred after 6 cycles of chemotherapy. Primary endpoints were the ability to deliv...